The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1425
Influenza Vaccine for 2013-2014
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Annual vaccination against influenza A and B viruses has been shown to decrease influenza illness and its complications. Several new vaccines are available for the current season.

VACCINE COMPOSITION — This year's seasonal trivalent influenza vaccines contain the following three strains: A/California/7/2009 H1N1-like, A/Victoria/361/2011 H3N2-like, and B/Massachusetts/2/2012-like. Quadrivalent vaccines will also include B/Brisbane/60/2008-like to provide additional protection against influenza B viruses.1

LIVE VS. INACTIVATED VACCINE — The intranasal live-attenuated influenza vaccine (LAIV), FluMist Quadrivalent, is recommended for use only in healthy, non-pregnant persons 2-49 years old. In children, the LAIV appears to be more effective than the inactivated influenza vaccine (IIV).2 In adults, the IIV has been ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Influenza Vaccine for 2013-2014
Article code: 1425a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian